BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AL8326 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AL8326\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06794957-2275@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AL8326: Phase 1 readout est. (NCT06794957)
DESCRIPTION:AL8326\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of AL8326 in Non-Small Cell Lung Cancer\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/al8326#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067949
 57
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363280-2275@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AL8326: Phase 2 readout est. (NCT05363280)
DESCRIPTION:AL8326\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase 2 
 Study for the Patient\, Who Has Diagnosed With Small Cell Lung Cancer (SCL
 C) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and
  Finished the First Line Stand Treatment \, Need More Treatment\nEstimated
  primary completion: December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/al8326#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05363280
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247605-2275@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:AL8326: Phase 3 readout est. (NCT06247605)
DESCRIPTION:AL8326\, phase 3\, Small Cell Lung Cancer.\nStudy: A Phase IIII
  Study of AL8326 in Small Cell Lung Cancer\nEstimated primary completion: 
 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/al8326#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0624760
 5
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392736-2275@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20291107
DTEND;VALUE=DATE:20291108
SUMMARY:AL8326: Phase 1/2 readout est. (NCT07392736)
DESCRIPTION:AL8326\, phase 1/2.\nStudy: A Phase I/IIa Study of AL8326 Combi
 ned With Toripalimab in the Treatment of Advanced Solid Tumors.\nEstimated
  primary completion: 7 November 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/al8326#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07392736
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811232-2275@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:AL8326: Phase 1/2 readout est. (NCT07811232)
DESCRIPTION:AL8326\, phase 1/2.\nStudy: A Study of AL58805 in Advanced\, Me
 tastatic GYN\, STS or Breast Cancers\nEstimated primary completion: 1 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/al8326#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078112
 32
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
